Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2022 Sep 14;30(9):1194-1195.
doi: 10.1016/j.chom.2022.08.010.

A counterintuitive antibody cocktail disrupts coxsackievirus

Seth J Zost  1 , Matthew R Vogt  2
Affiliations
Comment

A counterintuitive antibody cocktail disrupts coxsackievirus

Seth J Zost et al. Cell Host Microbe. .

Abstract

Utilizing monoclonal antibodies to prevent and treat infectious diseases has been accelerated by the COVID-19 pandemic. In this issue of Cell Host & Microbe, Zheng et al. show how a three-monoclonal-antibody cocktail, that defies conventions of "rational design" for a therapeutic agent, functions cooperatively to disrupt coxsackievirus virions.

PubMed Disclaimer

Conflict of interest statement

Declaration of interests M.R.V. is a paid consultant for IDBiologics, Inc. and is co-inventor on a patent application for anti-enterovirus D68 human monoclonal antibodies filed by Vanderbilt University. S.J.Z. is a co-inventor on patent applications for anti-SARS-CoV-2 human monoclonal antibodies filed by Vanderbilt University.

Comment on

References

    1. Baum A., Fulton B.O., Wloga E., Copin R., Pascal K.E., Russo V., Giordano S., Lanza K., Negron N., Ni M., et al. Antibody cocktail to SARS-CoV-2 spike protein prevents rapid mutational escape seen with individual antibodies. Science. 2020;369:1014–1018. doi: 10.1126/science.abd0831. - DOI - PMC - PubMed
    1. Chen P., Nirula A., Heller B., Gottlieb R.L., Boscia J., Morris J., Huhn G., Cardona J., Mocherla B., Stosor V., et al. SARS-CoV-2 Neutralizing Antibody LY-CoV555 in Outpatients with Covid-19. N. Engl. J. Med. 2021;384:229–237. doi: 10.1056/nejmoa2029849. - DOI - PMC - PubMed
    1. Gilchuk P., Murin C.D., Cross R.W., Ilinykh P.A., Huang K., Kuzmina N., Borisevich V., Agans K.N., Geisbert J.B., Zost S.J., et al. Pan-ebolavirus protective therapy by two multifunctional human antibodies. Cell. 2021;184:5593–5607.e18. doi: 10.1016/j.cell.2021.09.035. - DOI - PMC - PubMed
    1. Johnson S., Oliver C., Prince G., Hemming V., Pfarr D., Wang S., Dormitzer M., O'Grady J., Koenig S., Tamura J., et al. Development of a humanized monoclonal antibody (MEDI-493) with potent in vitro and in vivo activity against respiratory syncytial virus. J. Infect. Dis. 1997;176:1215–1224. doi: 10.1086/514115. - DOI - PubMed
    1. Mulangu S., Dodd L.E., Davey R.T., Jr., Tshiani Mbaya O., Proschan M., Mukadi D., Lusakibanza Manzo M., Nzolo D., Tshomba Oloma A., Ibanda A., et al. A Randomized, Controlled Trial of Ebola Virus Disease Therapeutics. N. Engl. J. Med. 2019;381:2293–2303. doi: 10.1056/nejmoa1910993. - DOI - PMC - PubMed

Substances